Homepage038290 • KOSDAQ
add
Macrogen Inc
Vorige slotkoers
₩ 15.730,00
Dag-range
₩ 15.650,00 - ₩ 15.810,00
Jaar-range
₩ 14.700,00 - ₩ 19.150,00
Beurswaarde
171,29 mld. KRW
Gem. volume
18,65K
Koers/winst
-
Dividendrendement
1,90%
Primaire beurs
KOSDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (KRW) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 48,99 mld. | 62,40% |
Bedrijfskosten | 18,19 mld. | 44,00% |
Netto inkomsten | -1,59 mld. | 44,84% |
Netto winstmarge | -3,24 | 66,04% |
Winst per aandeel | — | — |
EBITDA | 1,17 mld. | -4,30% |
Effectief belastingtarief | 2,39% | — |
Balans
Totale activa
Totale passiva
| (KRW) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 31,78 mld. | 13,27% |
Totale activa | 323,58 mld. | 20,15% |
Totale passiva | 158,16 mld. | 33,97% |
Totaal aandelenvermogen | 165,42 mld. | — |
Uitstaande aandelen | 10,84 mln. | — |
Koers-boekwaardeverhouding | 1,13 | — |
Rendement op activa | -1,16% | — |
Rendement op kapitaal | -1,48% | — |
Kasstroom
Nettomutatie in liquide middelen
| (KRW) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -1,59 mld. | 44,84% |
Operationele kasstroom | -760,84 mln. | -122,09% |
Kasstroom uit beleggingen | -7,77 mld. | -58,00% |
Kasstroom uit financiering | -262,41 mln. | -102,98% |
Nettomutatie in liquide middelen | -9,51 mld. | -251,93% |
Vrije kasstroom | -32,89 mld. | -762,38% |
Over
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Opgericht
5 jun 1997
Website
Werknemers
500
